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Abstract	
	The	calcium	signal	is	a	powerful	and	multifaceted	tool	by	which	cells	can	achieve	specific	outcomes.	Cellular	machinery	important	in	tumour	progression	are	often	driven	or	influenced	by	changes	in	calcium	ions,	in	some	cases	this	regulation	occurs	within	spatially	defined	regions.	Over	the	past	decade	there	has	been	a	deeper	understanding	of	how	calcium	signalling	is	remodeled	in	some	cancers	and	the	consequences	of	calcium	signalling	on	key	events	such	as	proliferation,	invasion	and	sensitivity	to	cell	death.	Specific	calcium	signalling	pathways	have	also	now	been	identified	as	playing	important	roles	in	the	establishment	and	maintenance	of	multidrug	resistance	and	the	tumour	microenvironment.		
	
Introduction	
	The	study	of	calcium	signalling	had	its	historic	roots	in	investigations	focused	on	excitable	cells	such	as	those	of	the	heart,	where	the	calcium	ion	(Ca2+)	was	identified	as	having	an	important	role	in	contraction	over	130	years	ago1.	Subsequent	to	these	early	studies,	the	Ca2+	signal	was	identified	as	a	key	regulator	of	processes	in	other	excitable	cells	such	as	neurons	and	in	non-excitable	cells2,	including	those	of	the	epithelia,	where	it	can	control	a	diverse	array	of	processes	such	as	secretion,	proliferation	and	gene	expression3.	It	is	therefore	understandable	that	researchers	can	overlook	a	protein	involved	in	Ca2+	homeostasis	when	identified	as	a	protein	of	interest	from	cancer	biopsies	or	a	siRNA	phenotypic	screen,	or	discount	Ca2+	signalling	when	it	is	identified	as	an	altered	pathway.	The	ubiquity	of	the	Ca2+	signal	can	make	it	seem	as	if	Ca2+	levels	could	have	no	possible	role	in	the	selective	regulation	of	oncogenic	machinery,	and	that	modulation	of	a	specific	Ca2+	channel	or	Ca2+	pump	would	not	be	able	to	avoid	drastic	adverse	effects	on	non-transformed	cells.			
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However,	the	ubiquity	of	the	Ca2+	signal	and	its	ability	to	differentially	regulate	a	variety	of	functions	simultaneously	in	the	same	cell,	has	driven	evolutionary	complexity	in	Ca2+	signalling	that	is	reliant	on	specific	Ca2+	channels,	pumps	and	
exchangers4.	The	selective	roles	of	specific	proteins	that	transport	Ca2+	are	reflected	in	the	clinical	use	of	pharmacological	inhibitors	of	L-type	voltage	gated	Ca2+	channels	in	the	treatment	of	hypertension5,	the	use	of	the	N-type	Ca2+	channel	blocker	ziconotide	for	the	treatment	of	severe	and	chronic	pain5,	and	drug	development	programs	focused	on	producing	specific	pharmacological	modulators	of	Ca2+	channels	to	treat	a	diverse	array	of	conditions5.	Indeed,	the	activity	of	many	of	the	Ca2+	pumps	and	channels	assessed	in	cancer	can	be	modulated	by	pharmacological	agents	(Table	1).		In	the	context	of	cancer,	there	is	often	significant	remodelling	in	the	expression	of	proteins	directly	involved	in	Ca2+	signalling6,7.	Moreover,	important	oncogenic	machinery	is	sensitive	to	regulation	by	specific	Ca2+	signals8,9.	Some	proteins	that	transport	Ca2+	ions	are	not	just	regulators	of	oncogenic	signalling	but	their	altered	expression	can	actually	be	an	initiator	of	some	cancers.	Evidence	for	the	direct	role	of	proteins	that	regulate	Ca2+	transport	in	the	initiation	of	tumours	is	seen	in	mice	heterozygous	for	the	loss	of	the	Golgi	calcium	pump	secretory	pathway	Ca2+-ATPase	1	(SPCA1;	encoded	by	the	gene	Atp2c1)	that	show	an	increased	occurrence	of	squamous	cell	tumours10.			In	this	Review,	we	provide	a	general	overview	of	the	more	complex	aspects	of	Ca2+	signalling	for	those	outside	the	field	and	highlight	the	diversity	of	Ca2+	channels	and	Ca2+	pumps	expressed	in	human	cells.	We	will	explore	how	these	proteins	regulate	specific	cellular	processes,	many	of	which	intersect	directly	with	processes	important	in	cancer	progression	(e.g.	proliferation,	invasion	and	cell	death).	Some	of	the	emerging	fields,	and	areas	requiring	further	study,	such	as	the	role	of	Ca2+	signalling	in	the	context	of	the	tumour	microenvironment	will	also	be	discussed.	Finally,	new	areas	that	have	progressed	significantly	over	the	past	decade	will	be	described,	such	as	the	role	of	calcium	signalling	in	controlling	pathways	important	in	therapeutic	resistance.		
	
[H1]	Calcium	channels,	pumps	and	exchangers		
	Unlike	many	other	cellular	signals,	Ca2+	is	not	created	from	an	enzymatic	reaction	or	destroyed	or	converted	to	an	inactive	metabolite11.	What	controls	the	often	complex	changes	in	Ca2+	levels	in	the	cytosol	and	sub-cellular	organelles	are	the	instruments	of	Ca2+	homeostasis	–	Ca2+	pumps,	channels	and	exchangers11.	These	and	other	proteins	involved	in	calcium	homeostasis	and	signalling	have	been	described	as	the	calcium	signalling	“tool	kit”12	and	are	the	means	by	which	cells	orchestrate	specific	biological	events.	Some	of	the	key	classes	of	proteins	involved	in	the	influx,	efflux	and	sequestration	of	Ca2+	ions	in	mammalian	cells	are	presented	in	Figure	1,	and	have	been	previously	reviewed	elsewhere1,4,12.			 	There	is	a	low	level	of	cytosolic	free	Ca2+	([Ca2+]CYT)	(~100	nM)	compared	to	the	level	of	free	Ca2+	in	most	extracellular	fluids	(>	1	mM),	creating	a	large	
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concentration	gradient	that	promotes	the	influx	of	Ca2+	into	the	cell	when	Ca2+	permeable	ion	channels	are	open1.		Ca2+	permeable	ion	channels	are	classified	depending	on	the	genes	that	encode	their	components	and	their	functional	properties.	Voltage-gated	Ca2+	channel	component	subunits	are	encoded	by	a	variety	of	genes	and	can	also	be	classified	by	their	electrophysiological	properties5.	Transient	receptor	potential	(TRP)	ion	channels	are	another	diverse	family,	which	include	ion	channels	with	high	selectivity	for	Ca2+	and	potential	constitutive	activity	(e.g.	TRPV6),	as	well	as	temperature	sensitive	channels	such	as	the	cold	sensor	TRPM8	and	the	heat	and	capsaicin	(hot	chilli	component)	sensitive	TRPV113.	There	are	at	least	20	ion	channels	encoded	by	TRP	genes	in	mammals14	and	heteromeric	associations	of	channel	subunits	may	yield	further	functional	diversity13.	Another	important	Ca2+	channel	is	calcium	release-activated	calcium	channel	protein	1	(ORAI1),	involved	in	a	mechanism	known	as	store	operated	calcium	entry	(SOCE),	which	is	detected	by	the	endoplasmic	reticulum	(ER)	Ca2+	sensor	stromal	interaction	molecule	1	(STIM1).	STIM1	proteins	are	redistributed	upon	calcium	store	depletion	and	subsequently,	interact	with	ORAI1	proteins	found	at	the	plasma	membrane	leading	to	activation	of	Ca2+	influx15	(Fig	1).	ORAI1	related	isoforms	include	ORAI2	and	ORAI3,	and	heteromeric	channels	composed	of	ORAI	isoforms	may	constitute	channels	with	unique	properties16.			Moving	from	influx	to	efflux,	the	efflux	of	Ca2+	ions	occurs	against	a	concentration	gradient	and	therefore	necessitates	an	active	transport	system	using	ATP	cleavage	or	ion	gradients.	Plasma	membrane	Ca2+-transporting	ATPases	(PMCAs)	are	an	example	of	an	efflux	pump	with	four	genes	that	generate	a	plethora	of	functionally	and	regulatory	diverse	transporters	via	alternative	splicing17.	Plasmalemmal	sodium	(Na+)/Ca2+exchangers	are	examples	of	Ca2+	efflux	mechanisms	using	the	Na+	gradient,	and	include	SLC8A1	(also	known	as	NCX1)18.		
	Subcellular	organelles	such	as	the	ER,	mitochondria	and	the	Golgi	also	have	mechanisms	to	increase	and	decrease	Ca2+	levels	including	calcium	permeable	ion	channels,	pumps	and	exchangers	(Fig	1).	The	ER	plays	a	crucial	role	in	the	signalling	of	many	G-protein	coupled	receptors	(GPCRs)	through	the	expression	of	Ca2+	permeable	inositol	1,4,5-trisphosphate	receptor	(IP3R)	channels	that	respond	to	IP3	generated	from	phospholipase	C	(PLC)	mediated	cleavage	of	phosphatidylinositol	4,5-bisphosphate	(PIP2)2.	Following	Ca2+	release	into	the	cytoplasm	through	IP3Rs,	an	active	transport	system	mediated	by	sarcoplasmic/ER	Ca2+-ATPases	(SERCA1,	SERCA2	and	SERCA3)	can	sequester	Ca2+	back	into	the	Ca2+	rich	ER	lumen19.	Similarly	the	Golgi	has	sequestration	mechanisms	via	the	pumps,	SPCA1	and	SPCA2	that	can	also	transport	manganese	(Mn2+)	ions19.	Two	pore	channels	(TPC1	and	TRP2)	are	ion	channels	with	a	reported	ability	to	regulate	Ca2+	release	from	components	of	the	endolysosomal	system20.	Ca2+	levels	within	mitochondria	are	controlled	by	key	molecular	components21	that	include	multiple	proteins	contributing	to	the	mitochondrial	calcium	uniporter	(MCU)	complex,	and	at	least	one	molecularly	defined	Ca2+	efflux	mechanism	-	a	Na+/Ca2+	exchanger	encoded	by	the	gene	NCLX	(also	known	as	SLC8B1)21.		
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[H1]	Calcium:	ubiquitous	but	selective		
	When	Ca2+	levels	change	in	response	to	a	stimulus,	the	nature	of	these	changes	are	‘decoded’	by	cells	to	achieve	specific	cellular	outcomes.	The	complexity	of	Ca2+	signals	and	how	these	can	differentially	regulate	diverse	cellular	processes	has	been	elegantly	reviewed	by	a	number	of	researchers12,22,23.	Put	simply,	Ca2+	signals	can	vary	in	their	magnitude	as	well	as	in	their	spatial	and	temporal	characteristics.	In	a	single	cell,	large	sustained	increases	in	Ca2+	may	be	associated	with	cell	death,	while	highly	localised	changes	in	Ca2+	levels	in	the	cytosol	may	regulate	directional	migration24,25.	Ca2+	changes	in	mitochondria	can	control	mitochondrial	ATP	levels,	and	the	frequency	and	duration	of	[Ca2+]CYT	oscillations	can	differentially	activate	transcription	factors26,27.	Examples	of	the	diversity	in	Ca2+	signals	and	some	of	the	consequences	of	such	changes	are	depicted	in	Figure	2.			Recent	studies	using	a	variety	of	methods	to	assess	Ca2+	signals	(Box1)	have	provided	insight	into	the	molecular	pathways	by	which	nuanced	changes	in	Ca2+	can	achieve	specific	cellular	outcomes.	Two	recent	exemplars	relate	to	gene	transcription.	The	calcium	dependent	transcription	factors	nuclear	factor	of	activated	T	cells 1 (NFAT1)	and	NFAT4	are	differentially	regulated	by	ORAI1-mediated	Ca2+	influx	through	the	spatial	nature	of	changes	in	Ca2+.	Localised	increases	in	Ca2+	around	sites	of	ORAI1-mediated	Ca2+	entry	are	sufficient	to	activate	NFAT1,	but	NFAT4	activation	requires	this	source	of	Ca2+	in	combination	with	increases	in	the	level	of	free	Ca2+	within	the	nucleus28.	The	ability	of	the	L-type	voltage	gated	Ca2+	channel	CaV1.2	to	effectively	regulate	gene	transcription	via	cAMP	responsive	element-binding	protein	(CREB)	requires	local	Ca2+	changes	through	Ca2+	influx	then	subsequent	voltage-dependent	conformational	changes	in	the	CaV1.2	protein	itself	29.	The	temporal	gap	between	these	two	events	represents	a	further	level	of	control	(optimal	at	10-20	s),	and	the	misaligning	of	these	two	events	is	a	feature	of	a	mutation	associated	with	autism	spectrum	disorder	symptoms	in	patients	with	the	multisystem	disorder	Timothy	syndrome29.	The	aforementioned	studies	highlight	a	path	for	future	work	in	cancer	research,	especially	given	the	role	of	calcium	dependent	transcription	factors	such	as	NFAT	in	various	aspects	of	cancer	progression30.			As	will	be	discussed	below,	we	now	have	an	understanding	that	the	calcium	toolkit	is	often	remodelled	with	tumourigenesis	and	that	the	calcium	signal	can	regulate	key	oncogenic	and	tumour	suppressor	machinery	and	pathways.	
	
[H1]	Ca2+	signal	remodelling	in	cancer		
	
[H3]	Expression	remodelling	Alterations	in	the	expression	of	specific	Ca2+	channels	and	pumps	have	been	widely	reported	in	several	cancer	types.	Changes	in	expression	can	be	an	early	event	in	cancer	development,	such	as	the	down	regulation	of	SERCA3	during	colon	carcinogenesis31.	Expression	changes	in	a	single	Ca2+	channel	and/or	pump	can	be	a	common	feature	across	multiple	cancer	types,	such	as	the	reported	
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overexpression	of	TRPM8	in	cancers	of	the	prostate,	breast,	colon,	pancreas	and	lung32,33,	or	expression	changes	may	be	specific	to	subtypes	within	cancers	of	the	same	origin,	such	as	elevated	SPCA1	mRNA	in	basal	molecular	breast	cancers	compared	with	other	molecular	subtypes	of	breast	cancer34.	It	is	also	clear	that	changes	in	expression	of	multiple	Ca2+	channels	and/or	pumps	can	occur	in	the	same	cancer	type	or	even	subtype,	as	reflected	in	elevated	levels	of	TRPM8	and	TRPV6	in	prostate	cancer	and	increased	levels	of	ORAI1	and	TRPV6	in	basal	molecular	breast	cancers	(see	Table	2).			Either	directly	or	indirectly,	the	consequences	of	changes	in	Ca2+	channel	or	pump	expression	can	often	be	linked	to	Ca2+-sensitive	oncogenic	pathways.	Examples	include	increased	ORAI1	channel	expression	promoting	Ca2+	oscillations	and	proliferative	pathways	in	oesophageal	squamous	cell	carcinoma	cells35,	and	SPCA2	overexpression	increasing	the	proliferation	and	growth	in	soft	agar	of	a	non-malignant	breast	epithelial	cell	line	-	MCF-10A36.	Some	cancers	are	associated	with	reduced	expression	of	a	calcium	transporter	and	such	changes	may	similarly	promote	specific	hallmarks	of	cancer37.	For	example,	the	plasmalemmal	calcium	pump	PMCA4,	is	down	regulated	in	colon	cancers,	intensifying	Ca2+	sensitive	proliferative	stimuli	through	reduced	Ca2+	efflux	38.	Similarly,	the	down	regulation	of	ORAI1	(and	consequently	SOCE),	during	the	transition	of	prostate	cancer	to	a	hormone-refractory	phenotype,	bestows	protection	against	diverse	apoptosis-inducing	pathways,	such	as	those	induced	by	the	SERCA	inhibitor	thapsigargin	(Table	1),	tumor	necrosis	factor	α	(TNFα)	and	cisplatin	and/or	oxaliplatin39.			In	the	past	decade	there	have	been	major	advances	in	the	understanding	of	differences	between	subtypes	of	the	same	cancer	and	the	molecular	drivers	behind	alterations	in	the	expression	of	proteins	involved	in	Ca2+	homeostasis.	For	example,	TRPV6	is	elevated	in	some	but	not	all	breast	cancer	subtypes33,40,	and	we	now	know	that	enhanced	copy	number	of	the	TRPV6	gene	region	is	a	feature	of	triple	negative	breast	tumours	and	also	breast	cancers	of	the	basal	molecular	subtype	(which	have	a	significant	overlap	with	the	triple	negative	subtype41,42).	Triple	negative	breast	cancer	is	a	subtype	for	which	new	targeted	therapies	are	required	as	this	tumour	type	lacks	the	oestrogen	receptor,	a	target	for	anti-oestrogen	therapy	and	HER2	(also	known	as	ERBB2),	a	target	for	the	monoclonal	antibody	therapy	trastuzumab41.	Indeed	women	with	tumours	with	higher	levels	of	TRPV6	mRNA	have	a	poorer	survival42.	Similarly,	in	prostate	cancer,	CACNA1D,	the	gene	encoding	CaV1.3	was	identified	as	hypo-methylated	in	TMPRSS2:ERG	fusion	positive	prostate	cancers	compared	with	fusion	negative	cancers,	and	as	a	consequence	leads	to	elevated	CACNA1D	mRNA	levels	in	TMPRSS2:ERG	fusion	positive	prostate	cancers43.	These	results	may	be	more	than	just	correlative	as	there	is	evidence	for	a	role	for	voltage	gated	Ca2+	channels	in	processes	which	may	be	important	in	prostate	cancer	cells.	For	example,	a	previous	study	had	shown	not	only	an	association	between	elevated	
CACNA1D	and	TMPRSS2:ERG	fusion	positive	prostate	cancers	but	also	that	pharmacological	inhibition	of	L-type	Ca2+	channels	(which	includes	Cav1.3)	suppresses	the	proliferation	of	PC3	prostate	cancer	cells44.	Moreover,	other	
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voltage	gated	Ca2+	channels	have	been	linked	to	processes	in	prostate	cancer	cells	including	neuroendocrine	induced	differentiation	and	proliferation45-48.		Recent	studies	have	begun	to	identify	a	role	for	microRNA	regulation	in	the	remodelling	of	the	expression	of	specific	calcium	transporters	in	some	cancers.	This	is	exemplified	by	the	ability	of	the	cancer	related	microRNA	miR-25	when	overexpressed	in	HeLa	cells	to	dramatically	reduce	levels	of	MCU,	as	well	as	the	association	between	high	levels	of	miR-25	and	low	levels	of	MCU	in	colon	cancer	cells,	the	consequence	of	which	may	be	reduced	apoptosis	sensitivity	in	some	types	of	cancers49.	Another	example	is	the	association	between	ORAI1	overexpression	(implicated	in	increased	proliferation)	and	reduced	miR-519	levels	in	some	colorectal	cancer	cell	lines	and	colorectal	cancer	tissues50.			Despite	the	profound	changes	in	the	expression	of	Ca2+	channels	and	pumps	that	can	occur	in	some	cancers,	it	is	important	to	note	that	changes	in	expression	per	se	are	not	necessarily	sufficient	to	make	a	contribution	to	oncogenic	machinery.	For	example,	the	overexpression	of	a	Ca2+	channel	without	constitutive	activity	may	have	no	consequence	on	proliferative	signalling	or	invasion	pathways	if	it	lacks	the	signals	required	for	its	activation.	In	terms	of	mechanism,	the	consequences	to	calcium	homeostasis	of	a	channel	remaining	open	may	be	far	more	significant	than	changes	in	its	expression.				
[H3]	Activity	remodelling		Ca2+	sensitive	tumour	promoting	pathways	could	be	effected	even	in	the	absence	of	altered	expression	of	Ca2+	channels	and	pumps	by	the	array	of	mechanisms	regulating	the	activity	of	calcium	channels	and	pumps,	including	activity	regulating	proteins	(e.g.	STIM1),	post-translational	modifications,	splicing	and	trafficking	36,51-55.	For	example	the	proteolytic	cleavage	of	some	Ca2+	channels	and	pumps	can	yield	either	inactive	or	more	active	forms	56-59,	and	in	the	case	of	proteolytic	cleavage	of	CaV1.2	can	produce	a	C-terminal	fragment	that	acts	as	a	transcription	factor54.	The	role	of	proteolytic	cleavage	requires	further	investigation	in	the	context	of	the	potential	roles	of	other	Ca2+	channels	and	pumps	in	cancer	models.			Further	complexity	is	introduced	when	considering	that	activation	mechanisms	may	be	altered	in	a	cancer	or	a	cancer	subtype.	For	example,	ORAI3	is	activated	by	Ca2+	store	depletion	and	contributes	to	SOCE	in	oestrogen	receptor	positive	but	not	in	oestrogen	negative	breast	cancer	cell	lines,	however,	the	mechanism	by	which	this	occurs	is	still	not	fully	understood60.	In	some	prostate	cancer	cells,	ORAI3	forms	a	heteromeric	channel	with	ORAI1	which	is	activated	by	arachidonic	acid61.	The	cellular	signaling	diversity	offered	by	dynamic	formation	of	various	heteromeric	channels	compared	with	monomeric	channels	may	provide	some	tumours	with	a	growth	advantage.	Indeed	the	switch	from	ORAI1	monomeric	channels	to	ORAI3–ORAI1	heteromeric	channels	in	prostate	cancer	cells	provides	resistance	to	apoptosis	through	reduced	SOCE	(due	to	reduced	Orai1	monomers)	and	increased	proliferative	signalling	via	arachidonic	acid	(as	a	result	of	increased	ORAI3–ORAI1	heteromers)61.	Clearly	the	calcium	signal	can	be	modulated	via	diverse	mechanisms,	not	simply	just	by	changes	in	expression.	
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In	some	cases	the	contribution	of	ion	channels	and	pumps	is	attributed	to	indirect	effects	or	even	to	functions	independent	of	their	own	ion	transport	abilities36,62-65.	ORAI1-mediated	promotion	of	TRPV6	plasmalemmal	localisation	and	subsequent	enhancement	of	prostate	cancer	cell	proliferation63	is	one	such	example,	and	cleavage	of	TRPM7	(an	ion	channel	with	a	kinase	domain)	producing	kinase	domain	containing	fragments	capable	of	chromatin	remodelling	and	subsequent	changes	in	gene	expression66	is	another	example.	
	
[H1]	Ca2+	signal	intersection	with	cancer		Given	the	vital	role	of	Ca2+	signalling	in	so	many	cellular	processes1,4	it	is	unsurprising	that	the	calcium	signal	can	regulate	cancer	associated	processes	and	pathways.	However,	studies	have	identified	specific	contributions	of	Ca2+	homeostasis	in	selectively	regulating	oncogenic	and	tumour	suppressor	pathways	in	cancer	cells.	This	is	seen	in	the	ability	of	BAPTA-AM-mediated	chelation	of	[Ca2+]CYT	to	inhibit	epidermal	growth	factor	(EGF)-induced	phosphorylation	of	signal	transducer	and	activator	of	transcription	3	(STAT3)	without	inhibiting	EGF-induced	EGF	receptor	(EGFR),	ERK1	and	ERK2	or	AKT1	phosphorylation67.		Not	surprisingly	then,	the	examples	described	below	often	relate	to	nuanced	regulation	of	tumourigenic	pathways	by	Ca2+,	frequently	through	spatially	and/or	temporally	defined	changes	in	Ca2+.			Specific	examples	of	the	intersection	between	oncogenes,	tumour	suppressors	and	the	Ca2+	signal	include	the	association	between	H-RAS	driven	tumours	and	caveolin	1-dependent	changes	in	Ca2+	signalling68,	and	the	role	of	p53	in	increasing	pro-apoptotic	calcium	signals	within	mitochondria	through	increases	in	Ca2+	release	from	the	ER	via	direct	interactions	with	the	Ca2+	store	pump	SERCA269.	Figure	3	provides	an	overview	of	the	variety	of	processes	relevant	to	cancer	which	have	been	linked	to	changes	in	the	Ca2+	signal.	
	
[H3]	Ca2+	and	proliferative	signalling	in	cancer	cells	Ca2+	signalling	is	linked	to	specific	cell	cycle	events	and	its	importance	in	cellular	proliferation	including	the	mechanisms	by	which	this	regulation	occurs	have	been	previously	described7,8,70.	Changes	in	the	level	of	[Ca2+]CYT	occur	during	cell	cycle	progression	and	division71-73	and	key	steps	of	the	cell	cycle	are	Ca2+	signal	dependent	including	early	entry	into	G1	as	well	as	progression	through	the	G1/S	and	G2/M	stages8.	The	cell	cycle	events	that	are	Ca2+-sensitive	during	cell	cycle	progression	include	but	are	not	limited	to,	the	early	induction	of	FOS,	JUN	and	
MYC,	the	phosphorylation	of	RB1,	the	activity	of	calmodulin	and	
Ca2+/calmodulin-dependent	protein	kinases	(CaMKs)	and	the	activity	of	a	variety	of	Ca2+	dependent	transcription	factors	including	NFAT,	CREB	and	nuclear	factor-	κB	(NF-κB)7,8,74.			However,	increased	Ca2+	is	clearly	not	solely	sufficient	for	proliferation,	as	it	is	the	nature	of	the	change	in	cytosolic	Ca2+	that	is	important	in	promoting	proliferation.	More	specifically,	if	increasing	Ca2+	was	all	that	was	required	for	cell	proliferation	then	interventions	that	increased	global	or	localised	Ca2+	levels	would	always	be	pro-proliferative.	This	is	plainly	not	the	case,	as	pharmacological	activation	of	TRPV4	channels	reduces	the	proliferation	of	tumour	endothelial	cells75	whilst	silencing	of	the	Ca2+	efflux	pump	PMCA2	
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reduces	the	proliferation	of	SKBR3	breast	cancer	cells76.	Hence,	the	role	of	the	calcium	signal	and	the	intersection	with	proliferation	is	context	dependent.		Changes	in	the	expression	or	activity	of	specific	calcium	channels	and	pumps	in	some	cancers	could	bestow	increased	sensitivity	to	genetic	or	pharmacological	modulation	of	these	proteins	compared	to	the	majority	of	normal	cells	in	the	body.	This	is	particularly	the	case	for	calcium	channels	and	pumps	that	are	not	ubiquitously	expressed	and	therefore	would	not	be	regarded	as	universal	regulators	of	cellular	proliferation.	This	is	highlighted	by	the	anti-proliferative	effects	of	experimental	TRPM8	inhibition	on	prostate	cancer	cells77;	this	effect	is	achieved	due	to	the	higher	levels	of	TRPM8	in	many	prostate	cancers	compared	with	the	normal	prostate	and	the	relatively	restricted	distribution	of	this	channel	in	other	tissues	32.	Many	studies	have	identified	specific	Ca2+	channels	or	pumps	whose	reduced	expression	and/or	pharmacological	inhibition	can	suppress	proliferation	of	cancer	cell	lines	in	vitro	and	in	vivo6,8,78-82.	One	recent	study	showed	that	in	a	mouse	model	of	HER2-overexpressing	breast	cancer,	deletion	of	PMCA2	resulted	in	less	tumour	growth76.	In	addition	to	suggesting	that	PMCA2	may	be	a	particularly	appropriate	therapeutic	target	for	HER2	positive	breast	cancers,	this	study	also	highlights	an	effective	and	new	approach	for	future	studies	wishing	to	define	the	role	of	other	calcium	channels	and	pumps	in	this	and	other	transgenic	animal	cancer	models.		
[H3]	Ca2+	signalling	in	the	primary	and	metastatic	tumour	
microenvironment		The	microenvironment	of	both	the	primary	tumour	and	metastatic	sites	is	a	key	player	in	tumor	progression37,83	and	the	calcium	signal	represents	a	potential	means	through	which	the	tumour	microenvironment	(e.g.	hypoxia,	pH,	immune	cells,	cancer	associated	fibroblast	secreted	factors)	can	signal	to	cancer	cells.	The	important	role	of	Ca2+	signals	in	the	diverse	cell	types	in	the	stroma	surrounding	the	primary	tumour	and	at	metastatic	sites	or	even	in	the	pre-metastatic	niche	and	how	these	might	contribute	to	disease	progression	is	still	relatively	unexplored.		
	The	tumour	microenvironment	is	a	driver	of	angiogenesis,	which	is	required	for	the	maintenance	of	tumour	growth84.	TRPV4	is	crucial	for	processes	important	to	tumour	angiogenesis,	as	reflected	in	its	upregulation	in	endothelial	cells	derived	from	breast	cancers	where	it	facilitates	arachidonic	acid-mediated	increases	in	[Ca2+]CYT	,	mechanosensitivity	and	migration85,86.	Indeed,	pharmacological	activation	of	TRPV4	enables	sub-therapeutic	doses	of	cisplatin	to	become	effective	in	suppressing	tumour	growth	in	a	syngeneic	mouse	model	of	Lewis	lung	carcinoma	by	partially	reversing	abnormal	tumour	vasculature86.			Alterations	in	Ca2+	signalling	in	cancer	cells	invoked	by	immune	cells	and	the	role	of	Ca2+	signalling	in	the	regulation	of	key	processes	in	immune	cells	is	another	example	of	the	interplay	between	Ca2+	signalling	and	cells	of	the	tumor	microenvironment.	C-C	motif	chemokine	18	(CCL18),	a	chemokine	released	from	tumor-associated	macrophages	and	that	promotes	breast	cancer	metastasis,	seems	to	act,	at	least	in	part,	via	Ca2+	signals	elicited	downstream	of	the	chemokine	receptor	membrane-associated	phosphatidylinositol	transfer	protein	
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3	(PITPNM3)	in	breast	cancer	cells87.	Interventions	in	ER	Ca2+	signalling	in	CD4+T-lymphcytes	are	a	proposed	mechanism	to	restore	some	immune	function	to	the	tumour	microenvironment88.	Furthermore,	there	is	a	direct	role	for	calcium	signals	in	regulating	cancer	cell	death	induced	by	cytotoxic	T	lymphocytes	and	natural	killer	cells	(reviewed	in	detail	in	ref.89).			The	calcium	signal	interacts	with	many	microenvironmental	factors	such	as	oxygen	tension,	pH,	growth	factors	and	other	signalling	molecules.	For	example,	STIM1	is	an	important	driver	of	hypoxia-mediated	changes	that	contribute	to	the	progression	of	hepatocarcinoma;	this	occurs	through	a	complex	mutual	interplay	whereby	STIM1-regulated	Ca2+	influx	increases	hypoxia-inducible	factor-1α	(HIF1α)	stability	and	HIF1α	in	turn	regulates	STIM1	transcription90.	The	ability	of	Ca2+	influx	to	regulate	hypoxia-mediated	increases	in	HIF1a	is	also	evident	in	glioma	cells	as	TRPC6-mediated	Ca2+	influx	regulates	HIF1a	hydroxylation	levels	and	thus	HIF1a	stability91.	The	acidic	nature	of	the	tumour	microenvironment	also	alters	cytosolic	and	mitochondrial	free	Ca2+	levels	via	acid-sensing	ion	channel	1	(ASIC1),	the	consequence	of	which	is	induction	of	reactive	oxygen	species	(ROS)	and	activation	of	NF-κB	in	breast	cancer	cells.	Indeed	silencing	of	ASIC1	reduces	tumour	growth	and	metastasis	in	an	in	vivo	mouse	xenograft	model92.			Cancer	cells	that	metastasise	will	have	different	requirements	for	survival	and	growth	at	the	metastatic	site	compared	with	that	of	the	primary	tumour.	An	integrated	genomic	and	transcriptomic	analysis	reported	that	lower	levels	of	the	intracellular	Ca2+	store	release	channel	IP3R1	(encoded	by	the	gene	ITPR1)	is	associated	with	metastasis	to	the	brain	but	not	to	other	organs93.	A	higher	propensity	for	mutations	which	were	predicted	to	be	deleterious	in	ITPR1	was	also	observed	in	brain	metastases	arising	from	breast	cancers93.	The	very	different	growth	environment	in	the	brain	may	be	favourable	for	the	selection	of	breast	cancer	cells	with	reduced	IP3R1	levels	and/or	activity,	which	may	confer	increased	resistance	to	cell	death	from	ER	stress	or	apoptotic	stimuli.	A	direct	example	of	the	interplay	between	cancer	cells	and	the	stromal	cells	of	the	metastatic	niche	is	found	in	the	establishment	of	abdominal	metastasis	in	serous	ovarian	cancer94.	This	metastatic	pathway	involves	Ca2+	signalling	in	ovarian	cancer	cells	induced	by	adipocytes	at	the	metastatic	niche.	More	specifically,	Ca2+	dependent	phosphorylation	of	salt-inducible	kinase	2	(SIK2)	in	ovarian	cancer	cells	leads	to	the	subsequent	activation	of	fatty	acid	oxidation	and	AKT	phosphorylation	and	as	a	consequence,	augmentation	of	proliferative	and	pro-survival	pathways94.	Another	example	of	the	potential	importance	of	the	metastatic	microenvironment	and	calcium	is	seen	in	the	proposal	that	high	levels	of	extracellular	Ca2+,	due	to	bone	remodeling,	is	a	driver	for	bone	metastasis	in	cancers	that	express	the	extracellular	Ca2+	sensing	receptor	(CaSR),	which	is	also	linked	to	the	proliferation	of	some	cancer	cell	lines	such	as	BT-474	and	MDA-MB-231	breast	cancer	cells	and	also	PC-3	prostate	cancer	cells95,96.	A	better	understanding	of	the	remodelling	of	Ca2+	signalling	in	cancer	cells	within	different	metastatic	sites	and	calcium	signalling	induced	by	stromal	cells	and	events	in	the	metastatic	niche,	may	help	to	define	a	novel	set	of	molecular	therapeutic	targets	and	provide	new	insights	into	disease	progression.	Such	studies	should	continue	to	be	the	focus	of	future	research.	
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[H3]	Ca2+	and	pathways	involved	in	cancer	cell	migration,	invasion	and	
metastasis		The	dissemination	of	cancer	to	other	organs	during	metastasis	requires	the	migration	and	invasion	of	cancer	cells	from	the	primary	tumour37.	Almost	every	step	in	the	migration	and	invasion	of	cancer	cells,	from	processes	that	influence	the	first	responses	to	pro-migratory	stimuli,	to	the	rate	of	movement,	directional	control,	and	the	release	of	enzymes	that	degrade	the	extracellular	matrix	have	some	degree	of	calcium	signal	dependence7,9,97.	Here,	we	highlight	some	specific	studies	to	provide	examples	of	the	mechanisms	by	which	the	calcium	signal	can	contribute	to	these	diverse	metastatic	processes.			Many	pro-migratory	signals	act	on	GPCRs	that	couple	to	pathways	that	can	mobilise	Ca2+	from	internal	stores.	One	example	is	the	activation	of	the	GPCR	protease	activated	receptor-1	(PAR1)	on	cancer	cells	by	matrix	metalloprotease-1	(MMP-1)	secreted	by	fibroblasts	of	the	tumour	stoma,	which	contributes	to	invasion	of	breast	cancer	cells98.	Studies	have	consistently	shown	clear	differences	in	the	nature	of	[Ca2+]CYT	signals	between	the	leading	and	trailing	edge	of	migrating	cells,	with	often	highly	polarised	and	localised	changes	in	free	Ca2+	and	consistently	higher	Ca2+	levels	at	the	trailing	edge99-102.	In	addition	to	contributing	to	forward	motion	through	activating	contractile	proteins	at	the	trailing	edge,	Ca2+	signalling	is	also	important	in	modifications	in	focal	and	peripheral	adhesion	molecules	often	through	effecting	turnover	via	Ca2+	dependent	phosphorylation	or	enzymatic	cleavage.	Furthermore,	Ca2+	changes	can	also	affect	key	cytoskeletal	proteins	throughout	the	cell9.	Silencing	of	components	of	SOCE	(ORAI1	or	STIM1)	or	pharmacological	inhibition	of	this	pathway	modulates	focal	adhesion	turnover	in	MDA-MB-231	cells	and	also	reduces	the	invasiveness	of	this	cell	line103.		Localised	calcium	changes	may	also	serve	to	maintain	the	polarised	cell	morphology	required	for	cell	migration104.	Transient	(~0.5	s)	high	levels	of	localised	Ca2+	at	the	leading	edge	of	migrating	cells,	termed	“Ca2+	flickers”,	control	the	direction	in	which	cells	move25.	These	studies	in	human	WI-38	lung	fibroblasts	identified	that	Ca2+	influx	through	TRPM7	in	addition	to	IP3	mediated	Ca2+	release	from	the	ER	was	crucial	in	responding	to	platelet	derived	growth	factor	(PDGF)	concentration	gradients	and	subsequent	directional	migration25.	The	aforementioned	studies	place	the	calcium	signal	as	both	the	navigator	and	a	key	component	of	the	engine	in	some	types	of	cell	motility	(Fig	2).	Further	work	is	now	required	to	define	the	Ca2+	channels	involved	in	these	specific	migration	modes	in	cancer	cells;	these	studies	will	need	to	assess	cancer	cells	originating	from	different	organs	as	different	cancers	may	exploit	different	types	of	Ca2+	channels	to	achieve	and	control	migration.		For	invasion	of	cancer	cells	through	the	extracellular	matrix,	Ca2+	influx	pathways	can	induce	the	expression	of	pro-invasive	enzymes,	such	as	particular	MMPs	and	cathepsin	B	as	observed	in	prostate	cancer	cells	via	the	Ca2+	permeable	ion	channel	TRPV2105.	Ca2+	influx	is	also	important	in	the	formation	of	
invadopodia	via	ORAI1-dependent	Ca2+	oscillations	in	melanoma	cells	which	occurs	in	part	through	promotion	of	SRC	(pY416)	phosphorylation106.	Ca2+	can	
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also	contribute	to	steps	in	the	metastatic	cascade	through	augmentation	of	other	pathways,	such	as	ROS	production,	which	subsequently	increases	cell	migration	in	lung	cancer	cells107,	and	cAMP	pathways,	which	increase	the	invasiveness	of	a	highly	metastatic	variant	of	MDA-MB-231	cells	in	vitro108.	Further	evidence	of	the	involvement	of	Ca2+	in	cancer	cell	migration,	invasion	and	metastasis	derives	from	silencing	and/or	pharmacological	inhibition	of	proteins	involved	in	Ca2+	signalling,	including	some	of	the	recently	identified	molecular	components	of	mitochondrial	Ca2+	regulation,	which	have	been	shown	to	inhibit	each	of	these	processes	(e.g.	ref103,105,109,110).	The	demonstrated	ability	to	inhibit	the	migration	of	MDA-MB-231	cells	in	vitro	and	the	growth	and	metastasis	of	MDA-MB-231	cells	to	the	lungs	in	vivo	in	a	mouse	xenograft	model	of	breast	cancer	by	silencing	MCU	(in	this	case	likely	through	lower	mitochondial	Ca2+	levels	reducing	mitochondrial	ROS	production	and	subsequently	HIF1a levels)	is	just	one	example	of	studies	that	have	defined	roles	for	specific	calcium	transporting	proteins	during	cancer	progression110.			Specific	tumour	microenvironmental	factors,	such	as	EGF	and	hypoxia	induce	epithelial	to	mesenchymal	transition	(EMT)	in	cancer	cells,	which	may	promote	increased	invasiveness	and	therapeutic	resistance111.	Ca2+	homeostasis	is	clearly	different	between	the	more	epithelial	and	the	more	mesenchymal	cell	phenotypes112-114,	with	attenuation	of	both	SOCE	and	ATP-mediated	changes	in	[Ca2+]CYT	occuring	as	a	consequence	of	EMT	in	MDA-MB-468	breast	cancer	cells	67,113-115.		Such	changes	in	Ca2+	signalling	are	perhaps	expected	given	the	major	changes	in	cellular	morphology	and	protein	expression	that	occur	as	a	result	of	EMT111.	However,	the	Ca2+	signal	itself	is	integral	to	the	induction	of	EMT,	and	ion	channels	such	as	TRPM7	and	TRPC6	can	differentially	contribute	to	the	induction	of	specific	EMT	associated	markers	in	different	models,	such	as	the	regulation	of	EGF-induced	vimentin	expression	by	TRPM7	in	MDA-MB-468	breast	cancer	cells67,116.	It	should	be	noted	that	the	contribution	of	Ca2+	channels	and	pumps	to	Ca2+	changes	during	cancer	cell	migration	and	invasion	will	likely	vary	between	cancer	types	and	with	the	nature	of	the	stimuli.		 	
[H3]	The	Ca2+	signal	and	cancer	cell	death		Ca2+	plays	an	important	role	in	pathways	relevant	to	cancer	cell	death2,7,8,24,82,117,118	and	the	remodelling	of	calcium	channel	or	pump	expression	may	allow	this	relationship	to	be	exploited	to	the	benefit	of	the	tumour.	For	example,	in	breast	cancer	cells,	the	overexpression	of	PMCA2	bestows	increased	resistance	to	cell	death	by	increasing	the	ability	of	cells	to	extrude	Ca2+	after	Ca2+	overload	induced	by	a	calcium	ionophore119.	In	some	cases	the	contribution	of	a	specific	protein	involved	in	calcium	signalling	may	be	through	localised	or	more	subtle	changes	in	Ca2+	signalling,	such	as	the	promotion	of	BCL-2	inhibitor	(ABT-263)-induced	cell	death	by	silencing	PMCA4	in	MDA-MB-231	cells	without	obvious	global	changes	in	[Ca2+]CYT	homeostasis120.				Although	much	remains	to	be	understood	about	the	precise	relationship	between	Ca2+	and	the	different	modes	of	cell	death,	it	is	clear	that	sustained	and	large	increases	in	[Ca2+]CYT	can	be	associated	with	necrotic	cell	death.	Ca2+	overload	by	pharmacological	activation	of	an	overexpressed	ion	channel121-123	or	
calcium	electroporation124	can	induce	necrosis	in	cancer	cells.	Accumulation	of	
	 12	
intracellular	Ca2+	can	also	trigger	necroptosis	in	human	neuroblastoma	cells	through	a	pathway	involving	phosphorylation	of	the	death	receptor	kinase	receptor	interacting	serine/threonine	protein	kinase	1	(RIPK1)	by	CaMKII125.		The	accumulation	of	Ca2+	ions	in	mitochondria	has	long	been	associated	with	apoptotic	cell	death,	with	the	increases	in	mitochondrial	matrix	Ca2+	induced	by	some	stimuli	or	stresses	contributing	to	the	opening	of	the	relatively	non	selective	mitochondrial	permeability	transition	pore	(a	collection	of	proteins)	that	contributes	to	the	loss	of	mitochondrial	membrane	integrity	and	the	subsequent	release	of	pro-apoptotic	factors	from	mitochondria117.	Additionally	there	is	a	complex	interplay	between	mitochondria,	apoptotic	regulating	BCL-2	family	members,	and	the	Ca2+	release	channels	of	the	ER126,127.	Some	cancer	cells	(e.g.	large	B-cell	lymphoma	cells)	are	sensitive	to	experimental	peptide-mediated	disruption	of	the	interaction	between	IP3Rs	and	BCL-2,	the	consequence	of	which	is	cell	death128,129.	The	intersection	between	calcium	stores,	cell	death	and	key	players	in	tumor	progression	in	cancer	cells	is	not	restricted	to	BCL-2.	In	addition	to	the	association	between	p53	and	ER	Ca2+	levels	via	effects	on	SERCA	activity	discussed	above69,	oncogenic	K-RAS	(K-RASG13D)	appears	to	attenuate	Ca2+	release	from	the	ER	following	apoptotic	stimuli,	which	subsequently	reduces	Ca2+	accumulation	in	the	mitochondria	and	promotes	colon	cancer	cell	survival130.	Alternatively,	the	tumour	suppressor	BRCA1	can	promote	Ca2+	release	from	the	ER	during	apoptosis	through	direct	effects	of	IP3Rs131.		The	relationship	between	the	IP3R	channels	of	internal	Ca2+	stores	and	mitochondria	is	also	evident	in	the	regulation	of	autophagy.	When	the	small	constitutive	Ca2+	release	from	IP3Rs	of	the	ER	to	the	mitochondria	(which	is	required	for	resting	mitochondrial	bioenergetics)	is	interrupted	(such	as	through	pharmacological	inhibition	of	IP3Rs	by	xestospongin	B),	pro-survival	autophagy	is	induced132.	However,	in	at	least	some	cancer	cell	lines	(e.g.	MCF-7	and	T47D	breast	cancer	cells),	the	disruption	of	this	ER	to	mitochondria	Ca2+	transfer	results	in	cell	death133.	Hence,	the	basal	uptake	of	Ca2+	into	mitochondria	via	this	pathway	is	essential	for	the	survival	of	some	cancer	cells	and	this	observation	adds	a	new	dimension	to	the	selective	targeting	of	malignancies	through	the	targeting	of	specific	and	localised	Ca2+	signals.	Clearly,	there	is	complex	interplay	between	mitochondria	and	the	ER	in	the	context	of	Ca2+	and	cell	death	sensitivity.	It	appears,	from	the	studies	described	above	that	many	cancers	differentially	remodel	this	interaction	to	achieve	a	survival	advantage.	The	significance	of	ER	Ca2+	is	not	restricted	to	IP3Rs	and	the	mitochondria.	This	is	recently	reflected	by	the	role	of	ryanodine	receptor	calcium	store	release	channels	in	TNF-related	apoptosis-inducing	ligand	(TRAIL)-mediated	apoptosis	in	MDA-MB-231	cells,	likely	through	calcineurin	dependent	activation	of	dynamin-1134.		
	
[H1]	The	Ca2+	signal	and	therapy	resistance	Some	of	the	major	recent	advances	in	our	understanding	of	the	nexus	between	calcium	signalling	and	cancer	are	provided	by	studies	assessing	how	the	calcium	signal	can	regulate	the	response	to	therapeutic	agents	and	the	acquisition	of	therapeutic	resistance.	Work	assessing	the	role	of	the	calcium	signal	in	augmenting	or	attenuating	responses	to	clinically	used	agents	has	produced	
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some	interesting	observations.	Recent	examples	include	the	promotion	of	the	in	
vitro	anti-proliferative	effects	of	low	concentrations	of	the	chemotherapeutic	agent	doxorubicin	by	PMCA2	silencing	in	MDA-MB-231	cells135,	and	the	sensitisation	of	human	ovarian	cells	to	carboplatin	chemotherapy	by	the	T-type	Ca2+	channel	blocker	mibefradil	in	an	in	vivo	xenograft	mouse	model136.			While	this	is	an	emerging	area,	more	mechanistic	detail	is	known	for	MCF-7	breast	cancer	cells	that	acquire	resistance	to	doxorubicin	.	These	cancer	cells	exhibit	increased	expression	and	function	(as	assessed	by	Ca2+	influx)	of	the	ion	channel	TRPC5.	As	a	consequence,	TRPC5	upregulation	results	in	increased	expression	of	multidrug	resistance	protein	1	(MDR1),	which	is	associated	with	resistance	to	several	chemotherapeutic	agents137.	Disrupting	TRPC5	expression	or	activity	by	gene	silencing	or	antibody	mediated	functional	inhibition	suppresses	the	induction	of	MDR1,	restoring	doxorubicin	sensitivity	in	resistant	MCF-7	cells	in	vitro	and	in	an	in	vivo	xenograft	mouse	model	of	breast	cancer137.	TRPC5	may	be	gained	by	a	cancer	cell	via	intercellular	transfer	of	extracellular	vesicles	containing	TRPC5138	leading	to	the	acquisition	of	resistance.	This	represents	a	powerful	way	for	cancer	cells	to	propagate	multidrug	resistance	within	a	tumour.	The	greater	levels	of	TRPC5	containing	extracellular	vesicles	in	women	with	breast	cancers	receiving	chemotherapy	is	further	support	for	an	important	role	for	this	calcium	signalling	mechanism	in	the	development	of	multidrug	resistance	in	some	patients	with	breast	cancer138.	Importantly	these	results	also	identify	an	alternative	therapeutic	approach	through	targeting	TRPC5,	to	overcome	MDR1-mediated	drug	resistance	without	global	pharmacological	inhibition	of	MDR1	activity.	The	recent	identification	that	TRPC5	silencing	reverses	the	resistance	to	the	chemotherapeutic	agent	5-fluorouracil	(5-FU)	in	HCT-8	and	LoVo	colorectal	cancer	cells139,	suggests	that	the	role	of	TRPC5	is	not	confined	to	breast	cancer,	and	that	further	exploration	of	the	role	of	TRPC5	and	potentially	other	calcium	channels	in	the	acquisition	and	propagation	of	multidrug	resistance	would	be	an	exciting	avenue	to	explore.		
		
[H1]	Targeting	the	calcium	signal		Throughout	this	review	we	have	highlighted	examples	of	how	the	silencing	and/or	pharmacological	inhibition	of	specific	Ca2+	permeable	ion	channels	or	pumps	attenuates	the	proliferation	or	invasiveness	of	cancers.	We	have	also	described	examples	where	Ca2+	influx	through	channel	activation	or	calcium	electroporation	can	promote	cancer	cell	death.	Indeed,	calcium	electroporation	is	currently	undergoing	a	clinical	trial	for	the	treatment	of	cutaneous	metastases	in	comparison	to	standard	electroporation	with	the	chemotherapeutic	agent	bleomycin	(NCT01941901)140.	Studies	have	also	shown	that	the	chelation	of	[Ca2+]CYT	greatly	reduces	the	induction	of	apoptosis	by	photodynamic	therapy	in	
vivo,	and	this	effect	may	be	dependent	in	at	least	some	cases	on	p53141.	Besides	these	observations,	other	opportunities	exist	to	target	the	calcium	signal	in	cancer.	For	example,	a	recent	study	highlights	an	exciting	avenue	of	exploration	and	is	reflective	of	the	expanse	and	potential	of	the	calcium-cancer	signalling	field	to	provide	novel	therapeutic	strategies	to	treat	cancer.	This	study	involved	an	epigenetic	screen	of	over	1000	FDA-approved	drugs,	in	addition	to	drugs	already	known	to	induce	epigenetic	changes.	From	this	screen,	11	drugs	with	the	
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ability	to	alter	Ca2+	signalling	were	identified	as	being	able	to	reverse	epigenetic-mediated	suppression	of	tumour	suppressor	genes	in	colon	cancer	cells	likely	through	CaMKs142.				The	demonstrated	ability	to	pharmacologically	modulate	Ca2+	channels	and	pumps	(Table	1),	provides	a	compelling	argument	that	when	Ca2+	signaling	is	implicated	in	a	tumour	progression	pathway,	a	specific	Ca2+	channel	or	pump	should	be	seriously	considered	as	a	potential	drug	target.	The	viability	and	phenotypes	of	knockout	animals	for	such	identified	targets,	as	well	as	the	effects	of	pharmacological	modulators	(if	available)	in	animal	models,	may	act	as	early	indicators	of	whether	such	proteins	may	be	appropriate	therapeutic	targets.	Indeed,	the	repurposing	of	existing	drugs	may	represent	rapid	opportunities	in	this	area.	
		One	case	in	point	is	the	interaction	between	K-RAS	and	calmodulin	and	the	subsequent	suppression	of	the	non-canonical	WNT	(or	WNT–Ca2+	signalling)	pathway,	which	is	crucial	for	K-RAS	oncogenesis143.	Disrupting	K-RAS–calmodulin	binding	was	described	as	a	unique	and	‘drug-able’	opportunity	to	target	K-RAS	in	pancreatic	cancer143.	However,	the	identification	of	Ca2+	channels	that	when	activated	or	inhibited	can	regulate	the	association	between	calmodulin	and	K-RAS	would	expand	the	therapeutic	target	repertoire	of	cancer	treatments.	Particularly	given	the	often	highly	localised	role	of	calcium	channels	in	the	regulation	of	CaMKII144,	which	is	a	key	conduit	in	this	K-RAS	malignant	pathway143.	
	There	are	clear	examples	(some	of	which	have	already	been	discussed	in	this	Review),	where	specific	isoforms	of	a	channel	or	pump	or	a	specific	heteromeric	channel	is	remodelled	or	contributes	to	a	particular	cancer	relevant	pathway.	Hence,	in	many	cases	the	optimal	target	may	be	a	specific	isoform	of	a	Ca2+	pump,	channel	or	even	a	specific	form	of	a	heteromeric	channel.	For	example,	PMCA4	but	not	PMCA1	silencing	promotes	ABT-263	mediated	cell	death	in	MDA-MB-231	cancer	cells,	but	this	is	not	due	to	a	more	important	role	for	PMCA4	in	global	Ca2+	regulation120.	Instead,	this	effect	is	likely	due	to	either	distinct	regulators	of	PMCA1	and	PMCA4,	or	the	different	contributions	of	the	isoforms	to	localised	Ca2+	signalling	due	to	their	potentially	different	locations	on	the	plasma	membrane	relative	to	other	proteins	and/or	their	different	affinities	for	the	Ca2+	ion	itself.	All	of	these	factors	would	have	an	impact	on	the	activation	of	downstream	Ca2+-sensitive	proteins.		One	of	the	newer	areas	addressed	in	this	review	has	been	the	consideration	of	Ca2+	signaling	in	the	context	of	the	microenvironment	of	the	primary	tumour	and	metastatic	sites.	These	areas	are	a	clear	opportunity	for	therapeutic	intervention	worthy	of	further	assessment.	In	addition	to	directly	targeting	those	Ca2+	channels	or	pumps	within	stromal	cells,	factors	in	the	tumour	microenvironment	may	also	be	directly	targeted	to	induce	Ca2+-mediated	effects	on	cancer	cells.	Such	is	the	case	for	a	SERCA	pump	inhibitor	in	the	form	of	a	thapsigargin-based	protease	activated	prodrug	(mipsagargin,	see	Table	1),	designed	to	be	activated	by	prostate	specific	membrane	antigen	(PSMA).	PMSA	is	rich	in	the	microenvironment	of	many	solid	tumours	and	therefore,	facilitating	a	localised	
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release	of	the	SERCA	pump	inhibitor	within	a	tumour	would	reduce	cancer	cell	viability,	whilst	avoiding	high	systemic	toxicity145.		This	agent	is	now	in	the	first	stages	of	clinical	assessment	for	refractory	prostate	cancer	therapy146.		
	
Conclusion	
	As	the	numerous	examples	outlined	above	attest	to,	the	calcium	signal	is	not	a	blunt	instrument	but	is	nuanced	and	contextual	and	is	intricately	involved	in	regulating	key	cellular	mechanisms	and	pathways.	How	the	signal	is	modulated	and	the	downstream	pathways	affected	may	contribute	to	outcomes	as	varied	as	the	evasion	of	cell	death	pathways,	cancer	cell	growth,	invasion	and	metastasis,	cancer	multi-drug	resistance,	and	the	regulation	of	tumour	growth	and	survival	by	the	primary	and	metastatic	tumour	microenvironments.	The	challenge	is	now	to	define	how	to	best	utilise	the	pharmacological	opportunities	offered	by	calcium	channels	and	pumps	to	selectively	target	these	processes	and	improve	patient	outcomes.			
		
	
	
	
References	
	
Acknowledgements:	This	work	is	supported	by	the	National	Health	and	Medical	Research	Council	of	Australia	(1079671	and	1079672).	GM	is	supported	by	the	Mater	Foundation.	The	Translational	Research	Institute	is	supported	by	a	grant	from	the	Australian	Government.			
Conflict	of	Interest	GM	and	SRT	are	associated	with	QUE-Oncology	Inc.	
	
	
Box	1:	Tools	for	the	assessment	of	calcium	signals	in	cancer	cells.			Small	molecule	based	probes	undergo	increases	in	fluorescence	upon	calcium	ion	(Ca2+)	binding	and	can	be	delivered	to	cells	as	an	acetomethyl	(AM)	ester147.	Probes	with	affinities	for	Ca2+	suitable	for	the	assessment	of	cytosolic	free	Ca2+	include	ratio-metric	probes	(dual	excitation,	e.g.	Fura-2,	or	dual	emission,	e.g.	Indo-1),	which	are	better	suited	to	account	for	variances	in	dye	loading148	and	single	wavelength	probes	that	typically	have	a	superior	dynamic	range	and	a	greater	repertoire	of	emission	and	excitation	wavelengths,	which	is	often	crucial	with	fluorescently	tagged	proteins.	Single	wavelength	probes	include	Fluo-4	and	Rhod-2,	which	have	green	and	red	fluorescence	emissions,	respectively149,150.			The	development	of	genetically	targeted	fluorescent	Ca2+	sensors	has	accelerated	in	recent	years	with	a	diversity	of	sensors	with	good	dynamic	ranges	now	available	that	can	be	targeted	to	specific	cellular	domains	or	organelles151,152.	
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	Small	molecule	and	genetically	targeted	Ca2+	sensors	are	available	with	different	affinities	for	Ca2+;	some	are	suited	to	the	assessment	of	the	high	Ca2+	levels	associated	with	certain	forms	of	cancer	cell	death	(e.g.	Fura-2FF153),	and	those	found	within	intracellular	organelles,	such	as	the	endoplasmic	reticulum	(e.g.	genetically	targeted	LAR-GECO	and	similar	sensors)	154.			Ca2+	levels	in	cells	can	be	assessed	using	a	variety	of	methods	from	low	throughput	cuvette	measurements	to	ultra-high	throughput	methods	using	microplates155.	Imaging	with	confocal,	multi-photon,	total	internal	reflection	fluorescence	(TIRF)	microscopy	and	fluorescence	lifetime	imaging	microscopy	(FLIM)	are	examples	of	other	approaches156-159.	Microscopic	assessment	can	be	carried	out	in	cells	lines,	isolated	tissue	or	even	in	vivo151	including	some	studies	in	tumour	masses	in	skin	folds141.	In	addition	to	these	light	based	approaches,	electrophysiology	methods	often	allow	nuanced	evaluation	and	characterisation	of	Ca2+	influx	mechanisms60.			
Fig	1:	Examples	of	Ca2+	permeable	ion	channels,	pumps	and	exchangers	of	
the	plasma	membrane	and	intracellular	organelles.	The	level	of	free	Ca2+	[Ca2+]	is	much	higher	in	the	extracellular	fluid	(ECF)	(>	1	mM)	compared	with	that	of	the	resting	free	calcium	in	the	cytosol	([Ca2+]CYT;	~	100	nM).	This	gradient	is	maintained	by	the	active	transport	of	Ca2+	across	the	plasma	membrane	via	the	plasma	membrane	Ca2+-transporting	ATPase	(PMCA)	pumps.	This	pump	can	also	contribute	to	the	decline	in	[Ca2+]CYT	levels	after	cell	stimulation.	One	mechanism	to	increase	[Ca2+]CYT	is	the	opening	of	plasma	membrane	Ca2+	permeable	ion	channels	such	as	those	that	are	voltage	gated	(subdivided	into	L-type,	T-type,	P/Q-type,	R-type	and	N-type;	an	example	of	an	L-type	channel	is	shown),	or	members	of	the	transient	receptor	potential	(TRP)	family,	such	as	the	cool	and	menthol	(found	in	mint)	activated	TRPM8,	the	heat	and	capsaicin	(found	in	hot	chilli	peppers)	activated	TRPV1,	and	the	highly	Ca2+	selective	channel,	TRPV6	that	has	constitutive	activity	in	some	cells.	[Ca2+]CYT	levels	can	also	increase	by	Ca2+	store	release,	such	as	via	inositol	1,4,5-trisphosphate	(IP3),	which	activates	the	IP3	receptors	(IP3Rs)	of	the	endoplasmic	reticulum	(ER).	This	IP3	can	be	generated	by	stimulation	of	some	G-protein-coupled	receptors	(GPCRs)	or	receptor	tyrosine	kinases	(such	as	the	epidermal	growth	factor	receptor	(EGFR),	through	activation	of	phospholipase	Cβ	(PLCb)	and	PLCg	isoforms,	respectively.	The	depletion	of	these	intracellular	Ca2+	stores	is	detected	by	the	Ca2+	sensor	stromal	interaction	molecule	1	(STIM1),	which	can	activate	an	calcium	release-activated	calcium	channel	protein	1(ORAI1)	dependent	Ca2+	influx	pathway	to	promote	Ca2+	store	refilling	through	the	Ca2+	sequestration	pump	-	the	sarcoplasmic/ER	Ca2+-ATPase	(SERCA).	Ca2+	sequestration	into	the	Golgi	is	mediated	by	a	secretory	pathway	Ca2+-ATPase	(SPCA),	which	can	also	actively	transport	Mn2+	ions.	Other	intracellular	organelles	have	Ca2+	transporting	proteins,	such	as	the	mitochondrial	calcium	uniporter	(MCU)	and	the	mitochondrial	Na+/Ca2+	exchanger	(NCLX)	and	the	two	pore	channels	(TPC)	of	lysosomes.	Note	that	some	of	the	transporters	shown	have	multiple	isoforms,	and	not	all	regulators	nor	all	families	of	Ca2+	permeable	ion	channels,	pumps	or	exchangers	are	depicted79,82,160-164.	NAADP,	nicotinic	acid	adenine	dinucleotide	
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phosphate.			
Fig	2:	Ca2+	signal	diversity.	This	figure	illustrates	the	diversity	in	Ca2+	signalling	and	how	this	may	contribute	to	processes	that	are	relevant	in	the	context	of	cancer	progression.	This	diversity	in	Ca2+	signalling	and	its	consequences	include,	but	are	not	limited	to:	A)	The	degree	of	increase	in	cytosolic	free	calcium	([Ca2+]CYT)	(amplitude	modulation	-	AM),	which	may	control	cell	fate	(e.g.	proliferation	or	cell	death);	the	different	coloured	lines	on	the	graph	represent	cytosolic	Ca2+	increases	of	different	amplitude.	B)	The	frequency	of	[Ca2+]CYT	oscillations	(frequency	modulation	-	FM),	which	may	control	the	nature	of	gene	transcription	and	hence	different	cellular	outcomes	and	expression	remodelling;	the	different	coloured	lines	on	the	graph	represent	cytosolic	Ca2+	increases	of	different	oscillation	frequencies.		C)	Highly	localised	and	transient	increases	in	Ca2+	at	the	edge	of	some	cells	(Ca2+	flickers),	which	control	directional	migration;	D)	Free	Ca2+	levels	within	the	endoplasmic	reticulum	(ER)	that	may	influence	cell	stress	and	the	sensitivity	to	apoptotic	stimuli,	which	act	in	part	through	the	release	of	Ca2+	from	internal	stores;	E)	the	confined	transfer	of	Ca2+	ions	from	the	ER	to	the	mitochondria	that	when	reduced	may	induce	autophagy	or	even	death	in	some	cancer	cells;	F)	Levels	of	Ca2+	ions	within	the	mitochondrial	matrix	where	modest	changes	may	promote	ATP	synthesis	but	sustained	high	levels	may	promote	cell	death;	G)	Localized	very	high	levels	of	Ca2+	(known	as	Ca2+	microdomains)	achieved	upon	the	opening	of	plasmalemmal	Ca2+	channels	can	specifically	regulate	gene	transcription	pathways.	In	some	cells,	Ca2+	bound	calmodulin	(CaM)	produced	near	the	opening	of	CaV1	channels	can	be	delivered	by	Ca2+/calmodulin-dependent	protein	kinase	II	subunit	gamma	(CaMKIIg)	to	the	nucleus	to	promote	the	phosphorylation	of	cAMP	responsive	element-binding	protein	(CREB)	and	gene	transcription;	in	other	cellular	systems,	localized	Ca2+	increases	produced	upon	the	opening	of	ORAI1	channels	is	sufficient	via	a	series	of	signalling	pathways	(indicated	by	the	small	dashed	arrow	and	the	‘+’	symbol)	to	produce	the	translocation	of	nuclear	factor	of	activated	T	cells 1	(NFAT1)	to	the	nucleus.	In	contrast	ORAI1-activated	gene	transcription	via	NFAT4	also	requires	increases	in	nuclear	Ca2+	(not	shown	on	this	figure).	Notes:	Δ	denotes	changes	in	a	pathway	or	levels,	­	denotes	an	increase	in	levels	or	activity.	Refs22,25,28,126,133,165-168.			
Fig	3.	The	calcium	signal	and	tumor	progression.	The	calcium	signal	often	intersects	through	specific	calcium	permeable	ion	channels	and	calcium	pumps,	with	a	variety	of	processes	relevant	to	the	growth,	metastasis	and	death	of	cancer	cells.	Refs8,9,67,68,82,85,86,89,93,94,117,124,127,133.	
	
Table	1:	Available	pharmacological	modulators	of	some	of	the	calcium	
(Ca2+)	permeable	ion	channels,	pumps	and	exchangers.	Where	possible	the	IUPHAR/BPS	Guide	to	pharmacology169	and	associated	material	has	been	used	to	construct	this	table.	Agents	that	have	been	widely	reported	to	have	effects	on	multiple	targets	(other	than	closely	related	isoforms)	have	not	been	listed	here	(refs79,82).			
Target	 Example	Inhibitor(s)	 Example	Activator(s)	
Ca2+	pumps	
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PMCA	 Caloxin	2A1170,	caloxin	1b3	(reported	to	be	more	selective	for	PMCA1)171,	caloxin	1b1	(more	selective	for	PMCA4)172	
-		
SERCA	 Thapsigargin,	cyclopiazonic	acid,	and	BHQ173,	mipsagargin	(prodrug)	145.		 Ochratoxin	A173.	
Ca2+	permeable	plasma	membrane	ion	channels	L-type	voltage	gated	Ca2+	channel	 Diltiazem,	nifedipine	verapamil174	 	(-)-(S)-BayK8644,	FPL64176,	SZ(+)-(S)-202-791174	T-type	voltage	gated	Ca2+	channel	 Mibefradil174	 	-	TRPC5	 ML204175	 (-)-englerin	A122.		TRPC6	 Larixyl	Acetate176	 Hyperforin177,178	TRPV1	 AMG517,	SB366791,	JNJ17203212177	 	 	Capsaicin,	Resiniferatoxin177.	TRPV4	 HC067047177	 GSK1016790A177.	TRPV6	 cis-22 a179	 -	TRPM7	 Waixenicin	A180,	NS8593181	 Mibefradil181	(note	also	a	T-type	Ca2+	channel	blocker)	TRPM8	 PF-05105679182,	M8-B183	 WS-12177,184	ORAI1-dependent	SOCE	 YM-58483185,	Synta66186,	GSK-7975A187	 -	
Endoplasmic	Reticulum	Ca2+	permeable	ion	channels	IP3Rs	 Xestospongin	B188	 Adenophostin	A188	IP3Rs,	inositol	1,4,5-trisphosphate	receptors;	ORAI1,	calcium	release-activated	calcium	channel	protein	1;	PMCA,	plasma	membrane	Ca2+-transporting	ATPases;	SERCA,	sarcoplasmic/endoplasmic	reticulum	Ca2+-ATPases;	SOCE,	store-operated	calcium	entry;	TRP,	transient	receptor	potential.		
	
Table	2:	Examples	of	similar	and	diverse	expression	remodeling	of	Ca2+	
permeable	ion	channels	in	breast,	prostate	and	colon	cancer:		Although	expression	changes	have	been	previously	tabulated6,82,	ion	channel	expression	studies	have	still	not	yet	been	assessed	sufficiently	across	different	cancer	types	to	make	a	comprehensive	identification	of	which	channels	if	any	may	be	universally	altered.	However,	it	is	already	clear	that	some	ion	channels	such	as	TRPV6	have	increased	expression	across	a	variety	of	cancer	types.	In	contrast,	ORAI1	is	upregulated	in	basal	molecular	breast	cancers	where	it	may	contribute	to	the	invasiveness	of	this	subtype,	yet	it	is	down	regulated	in	prostate	cancer	which	may	contribute	to	apoptotic	resistance.	Microenvironmental	factors	(hypoxia,	growth	factors,	pH)	may	also	contribute	to	expression	diversity	within	tumours	and/or	during	disease	progression.		
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Ca2+	
permeable	ion	
channel	
Cancer	Type		
Breast		 Prostate	 Gastric,	Colorectal	
ORAI1	 Increased	(basal	
subtype)189	
Decreased	
(castration-resistant	
)190	
Increased191,	192	
ORAI3	 Increased	
(oestrogen	receptor	
positive)	60	
Increased61	 not	assessed	
TRPV6	 Increased	(basal	
subtype	and	
oestrogen	receptor	
negative)42	
Increased193	 Increased	194,	195	
TRPC6	 Increased196	 Increased197	 Reduced198	
TRPM8	 Increased32,33,199,200	 Increased32,201,202	
	
Increased32	ORAI,	calcium	release-activated	calcium	channel	protein;	TRP,	transient	receptor	potential				
	
Glossary	
	
Ca2+	channel:	A	protein	or	group	of	proteins	which	form	a	Ca2+	ion	permeable	pore	across	a	membrane	which	can	be	opened	or	closed	by	different	stimuli.	
Ca2+/calmodulin-dependent	protein	kinases	(CaMKs):	Serine/Threonine	protein	kinases	whose	activation	is	usually	dependent	on	binding	to	calmodulin	(CaM)	in	the	Ca2+	bound	state.		
Ca2+	pump:	A	protein	which	through	the	hydrolysis	of	ATP	can	transport	Ca2+	ions	against	a	concentration	gradient	also	referred	to	as	Ca2+-ATPases.	
Exchanger:	A	transporter	of	ions	which	involves	the	exchange	of	one	type	of	ion	or	ions	for	another	type	across	a	membrane	which	does	not	involve	the	direct	cleavage	of	ATP.	
Store	operated	calcium	entry	(SOCE):	A	Ca2+	influx	pathway	activated	upon	the	depletion	of	intracellular	endoplasmic	reticulum	Ca2+	stores.	The	canonical	pathway	involves	Ca2+	influx	through	ORAI1	after	action	by	the	endoplasmic	reticulum	Ca2+	sensor	STIM1.	
Invadopodia:	Plasma	membrane	protrusions	associated	with	degradation	of	the	extracellular	matrix	which	is	important	in	cancer	cell	invasion.	
Calcium	ionophore:	A	chemical	moiety	that	can	facilitate	increases	in	[Ca2+]CYT	independent	of	Ca2+	channel	activation.	
Autophagy:	A	physiological	process	involving	degradation	of	the	cell’s	own	components,	which	can	be	initiated	by	nutrient	deficiency	and	can	aid	cell	survival.		
Extracellular	calcium-sensing	receptor:	A	plasmalemmal	G-protein	coupled	receptor	activated	by	changes	in	levels	of	extracellular	free	Ca2+.	
Calcium	electroporation:	A	process	whereby	an	electrical	field	which	increases	the	permeability	of	the	plasma	membrane	of	cells	is	applied	in	the	presence	of	raised	extracellular	Ca2+.		
Necroptosis:	A	regulated	form	of	necrotic	cell	death.		
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Key	Points		
• Calcium	is	a	ubiquitous	but	nuanced	cellular	signal;	it	regulates	functions	as	diverse	as	cell	motility,	cell	division	and	cell	death.	Precise	control	of	the	temporal	and	spatial	aspects	of	calcium	changes	allow	the	signal	to	achieve	specific	cellular	outcomes.	
• The	nature	of	the	calcium	signal	is	controlled	by	a	diverse	array	of	calcium	pumps,	channels	and	exchangers	present	on	the	plasma	membrane	and	membranes	of	intracellular	organelles.	Certain	cancers	are	associated	with	the	remodeling	of	the	expression	of	some	of	these	proteins.	
• Calcium	channels	and	pumps	are	amenable	to	targeting	by	pharmacological	agents.	
• Calcium	and	calcium	regulating	proteins	contribute	to	many	of	the	processes	key	to	cancer	cells,	including	proliferation,	invasion	and	cell	death.	A	number	of	oncogenes	and	tumour	suppressors	have	effects	on	calcium	homeostasis.		
• Calcium	signalling	in	the	tumour	microenvironment	is	likely	to	be	a	complex	interplay	between	a	number	of	different	stromal	cell	types	and	cancer	cells	and	represents	new	opportunities	for	therapeutic	intervention.	
• The	calcium	signal	is	a	critical	regulator	of	processes	associated	with	tumour	progression	including	epithelial	to	mesenchymal	transition	and	the	acquisition	of	specific	pathways	important	in	therapeutic	resistance.		
• The	application	of	new	methods	to	assess	calcium	signalling	in	vivo	and	over	long	periods	of	time	will	provide	new	insights	into	the	remodelling	
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of	calcium	signalling	in	cancer.		
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